Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Health Canada approves Aegerion Pharmaceuticals Inc' JUXTAPID capsules for treatment of homozygous familial hypercholesterolemia


Tuesday, 11 Feb 2014 08:00am EST 

Aegerion Pharmaceuticals Inc:Says that Health Canada has granted a Notice of Compliance approving JUXTAPID.Says Health Canada has granted JUXTAPID as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis, to reduce low-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia. 

Related Company News

Company Quote

22.81
-0.14 -0.61%
19 Dec 2014